Devon J. Shedlock, PhD, on Shifting from Autologous to Allogeneic Therapies

Video

The chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.

“We have developed an allogeneic CAR-T platform that we're expanding into TCRs. The nice thing about our platform is that because we're using the PiggyBac transposon technology, we’re able to have a larger CAR capacity. That easily enables the coexpression of a TCR along with a safety switch and a selection gene, with a CAR included as well.I think that's something that we can really leverage in our approach.”

Devon J. Shedlock, PhD, chief scientific officer, cell therapy, at Poseida Therapeutics, gave a presentation entitled “A Fully Allogeneic Tscm-based TCR-T Platform for Cncology & Beyond” on Poseida’s emerging technologies at the 7th Annual CAR-TCR Summit, held September 19-22, 2022, in Boston, Massachusetts.

Poseida Therapeutics is developing a pipeline of autologous and allogeneic chimeric antigen receptor (CAR) T-cell therapies for the treatment of both solid and liquid tumors, as well as rare diseases and hematological conditions. In his presentation, Shedlock discussed the company’s shift towards T-cell receptor (TCR) therapies and allogeneic therapies and the reasons behind this.

Shedlock discussed the Poseida’s TCR platform and its advantages in an interview with CGTLive. He touched on 2 of the company’s lead allogeneic programs right now, P-MUC1C-ALLO1 for solid tumors and P-BCMA-ALLO1 for multiple myeloma. He also shared his thoughts on why allogeneic CAR Ts are the future of the cell therapy space.

REFERENCE
Shedlock D. A fully allogeneic Tscm-based TCR-T platform for oncology & beyond. Presented at: 7th Annual CAR-TCR Summit. September 19-22, 2022; Boston, Massachusetts.
Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
© 2025 MJH Life Sciences

All rights reserved.